Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

Claudio Babiloni; Xianghong Arakaki; Hamed Azami; Karim Bennys; Katarzyna Blinowska; Laura Bonanni; Ana Bujan; Maria C. Carrillo; Andrzej Cichocki; Jaisalmer de Frutos-Lucas; Claudio Del Percio; Bruno Dubois; Rebecca Edelmayer; Gary Egan; Stephane Epelbaum; Javier Escudero; Alan Evans; Francesca Farina; Keith Fargo; Alberto Fernández; Raffaele Ferri; Giovanni Frisoni; Harald Hampel; Michael G. Harrington; Vesna Jelic; Jaeseung Jeong; Yang Jiang; Maciej Kaminski; Voyko Kavcic; Kerry Kilborn; Sanjeev Kumar; Alice Lam; Lew Lim; Roberta Lizio; David Lopez; Susanna Lopez; Brendan Lucey; Fernando Maestú; William J. McGeown; Ian McKeith; Davide Vito Moretti; Flavio Nobili; Giuseppe Noce; John Olichney; Marco Onofrj; Ricardo Osorio; Mario Parra-Rodriguez; Tarek Rajji; Petra Ritter; Andrea Soricelli; Fabrizio Stocchi; Ioannis Tarnanas; John Paul Taylor; Stefan Teipel; Federico Tucci; Mitchell Valdes-Sosa; Pedro Valdes-Sosa; Marco Weiergräber; Gorsev Yener; Bahar Guntekin

doi:10.1002/alz.12311

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

Claudio Babiloni^*, Xianghong Arakaki, Hamed Azami, Karim Bennys, Katarzyna Blinowska, Laura Bonanni, Ana Bujan, Maria C. Carrillo, Andrzej Cichocki, Jaisalmer de Frutos-Lucas, Claudio Del Percio, Bruno Dubois, Rebecca Edelmayer, Gary Egan, Stephane Epelbaum, Javier Escudero, Alan Evans, Francesca Farina, Keith Fargo, Alberto FernándezRaffaele Ferri, Giovanni Frisoni, Harald Hampel, Michael G. Harrington, Vesna Jelic, Jaeseung Jeong, Yang Jiang, Maciej Kaminski, Voyko Kavcic, Kerry Kilborn, Sanjeev Kumar, Alice Lam, Lew Lim, Roberta Lizio, David Lopez, Susanna Lopez, Brendan Lucey, Fernando Maestú, William J. McGeown, Ian McKeith, Davide Vito Moretti, Flavio Nobili, Giuseppe Noce, John Olichney, Marco Onofrj, Ricardo Osorio, Mario Parra-Rodriguez, Tarek Rajji, Petra Ritter, Andrea Soricelli, Fabrizio Stocchi, Ioannis Tarnanas, John Paul Taylor, Stefan Teipel, Federico Tucci, Mitchell Valdes-Sosa, Pedro Valdes-Sosa, Marco Weiergräber, Gorsev Yener, Bahar Guntekin

^*Corresponding author for this work

Medical Social Sciences

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

Original language	English (US)
Pages (from-to)	1528-1553
Number of pages	26
Journal	Alzheimer's and Dementia
Volume	17
Issue number	9
DOIs	https://doi.org/10.1002/alz.12311
State	Published - Sep 2021

Keywords

Alzheimer's disease
biomarkers
clinical trials
dementia
electroencephalography (EEG)
eyes-closed resting state condition
The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/alz.12311

Cite this

Babiloni, C., Arakaki, X., Azami, H., Bennys, K., Blinowska, K., Bonanni, L., Bujan, A., Carrillo, M. C., Cichocki, A., de Frutos-Lucas, J., Del Percio, C., Dubois, B., Edelmayer, R., Egan, G., Epelbaum, S., Escudero, J., Evans, A., Farina, F., Fargo, K., ... Guntekin, B. (2021). Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 17(9), 1528-1553. https://doi.org/10.1002/alz.12311

@article{7dab0a9ed79141fdba2ff81946766b87,

title = "Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel",

abstract = "The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.",

keywords = "Alzheimer's disease, biomarkers, clinical trials, dementia, electroencephalography (EEG), eyes-closed resting state condition, The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)",

author = "Claudio Babiloni and Xianghong Arakaki and Hamed Azami and Karim Bennys and Katarzyna Blinowska and Laura Bonanni and Ana Bujan and Carrillo, {Maria C.} and Andrzej Cichocki and {de Frutos-Lucas}, Jaisalmer and {Del Percio}, Claudio and Bruno Dubois and Rebecca Edelmayer and Gary Egan and Stephane Epelbaum and Javier Escudero and Alan Evans and Francesca Farina and Keith Fargo and Alberto Fern{\'a}ndez and Raffaele Ferri and Giovanni Frisoni and Harald Hampel and Harrington, {Michael G.} and Vesna Jelic and Jaeseung Jeong and Yang Jiang and Maciej Kaminski and Voyko Kavcic and Kerry Kilborn and Sanjeev Kumar and Alice Lam and Lew Lim and Roberta Lizio and David Lopez and Susanna Lopez and Brendan Lucey and Fernando Maest{\'u} and McGeown, {William J.} and Ian McKeith and Moretti, {Davide Vito} and Flavio Nobili and Giuseppe Noce and John Olichney and Marco Onofrj and Ricardo Osorio and Mario Parra-Rodriguez and Tarek Rajji and Petra Ritter and Andrea Soricelli and Fabrizio Stocchi and Ioannis Tarnanas and Taylor, {John Paul} and Stefan Teipel and Federico Tucci and Mitchell Valdes-Sosa and Pedro Valdes-Sosa and Marco Weiergr{\"a}ber and Gorsev Yener and Bahar Guntekin",

note = "Funding Information: Dr. Petra Ritter is supported by H2020 Research and Innovation Action grants VirtualBrainCloud 826421, Human Brain Project 785907, 945539, and ERC 683049; German Research Foundation CRC 1315, CRC 936, and RI 2073/6‐1; Berlin Institute of Health & Foundation Charit{\'e}, Johanna Quandt Excellence Initiative. Funding Information: Dr. Harald Hampel is an employee of Eisai Inc., serves as Senior Associate Editor for the journal . Before May 2019, he had received lecture fees, travel funding, and research grants from several Pharmacological Companies. Alzheimer's & Dementia Funding Information: Dr. Brendan Lucey is supported by the National Institute on Aging (K76 AG054863). Funding Information: Dr. Claudio Babiloni is supported by European Committee (H2020‐EU.1.3.1.H2020‐MSCA‐ITN‐ETN‐2016 project with short title “BBDiag”). Funding Information: The present paper was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the electrophysiology professional interest area (PIA). EPIA is committed to (1) exploit EEG biomarkers for improving the understanding of neurophysiological mechanisms underlying Alzheimer's disease and age-related dementing disorders at micro, meso, and macro spatial scale and (2) promoting clinical applications. Of note, the views and opinions expressed by authors in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART, or the Alzheimer's Association. Furthermore, this manuscript was facilitated by the Global Brain Consortium (https://globalbrainconsortium.org). The Global Brain Consortium is committed to achieving the vision of improved and more equitable health outcomes worldwide by strengthening linkages between neuroscientists across borders and disciplines. Quantitative EEG techniques and biomarkers are considered an important resource for brain research and clinical applications in neurologic and psychiatric diseases, especially in lower- and middle-income countries. We thank Prof. Philip Scheltens, Dr. Cornelius Stam, Dr. Wilhelm de Haan, and Dr. Alida Gouw of Center at the VU University Medical Center in Amsterdam for the constructive and helpful revision of an original version of the manuscript. We also thank Dr. Claire Sexton of Alzheimer's Association for the same reasons. Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",

year = "2021",

month = sep,

doi = "10.1002/alz.12311",

language = "English (US)",

volume = "17",

pages = "1528--1553",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "9",

}

Babiloni, C, Arakaki, X, Azami, H, Bennys, K, Blinowska, K, Bonanni, L, Bujan, A, Carrillo, MC, Cichocki, A, de Frutos-Lucas, J, Del Percio, C, Dubois, B, Edelmayer, R, Egan, G, Epelbaum, S, Escudero, J, Evans, A, Farina, F, Fargo, K, Fernández, A, Ferri, R, Frisoni, G, Hampel, H, Harrington, MG, Jelic, V, Jeong, J, Jiang, Y, Kaminski, M, Kavcic, V, Kilborn, K, Kumar, S, Lam, A, Lim, L, Lizio, R, Lopez, D, Lopez, S, Lucey, B, Maestú, F, McGeown, WJ, McKeith, I, Moretti, DV, Nobili, F, Noce, G, Olichney, J, Onofrj, M, Osorio, R, Parra-Rodriguez, M, Rajji, T, Ritter, P, Soricelli, A, Stocchi, F, Tarnanas, I, Taylor, JP, Teipel, S, Tucci, F, Valdes-Sosa, M, Valdes-Sosa, P, Weiergräber, M, Yener, G & Guntekin, B 2021, 'Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel', Alzheimer's and Dementia, vol. 17, no. 9, pp. 1528-1553. https://doi.org/10.1002/alz.12311

TY - JOUR

T1 - Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease

T2 - Recommendations of an expert panel

AU - Babiloni, Claudio

AU - Arakaki, Xianghong

AU - Azami, Hamed

AU - Bennys, Karim

AU - Blinowska, Katarzyna

AU - Bonanni, Laura

AU - Bujan, Ana

AU - Carrillo, Maria C.

AU - Cichocki, Andrzej

AU - de Frutos-Lucas, Jaisalmer

AU - Del Percio, Claudio

AU - Dubois, Bruno

AU - Edelmayer, Rebecca

AU - Egan, Gary

AU - Epelbaum, Stephane

AU - Escudero, Javier

AU - Evans, Alan

AU - Farina, Francesca

AU - Fargo, Keith

AU - Fernández, Alberto

AU - Ferri, Raffaele

AU - Frisoni, Giovanni

AU - Hampel, Harald

AU - Harrington, Michael G.

AU - Jelic, Vesna

AU - Jeong, Jaeseung

AU - Jiang, Yang

AU - Kaminski, Maciej

AU - Kavcic, Voyko

AU - Kilborn, Kerry

AU - Kumar, Sanjeev

AU - Lam, Alice

AU - Lim, Lew

AU - Lizio, Roberta

AU - Lopez, David

AU - Lopez, Susanna

AU - Lucey, Brendan

AU - Maestú, Fernando

AU - McGeown, William J.

AU - McKeith, Ian

AU - Moretti, Davide Vito

AU - Nobili, Flavio

AU - Noce, Giuseppe

AU - Olichney, John

AU - Onofrj, Marco

AU - Osorio, Ricardo

AU - Parra-Rodriguez, Mario

AU - Rajji, Tarek

AU - Ritter, Petra

AU - Soricelli, Andrea

AU - Stocchi, Fabrizio

AU - Tarnanas, Ioannis

AU - Taylor, John Paul

AU - Teipel, Stefan

AU - Tucci, Federico

AU - Valdes-Sosa, Mitchell

AU - Valdes-Sosa, Pedro

AU - Weiergräber, Marco

AU - Yener, Gorsev

AU - Guntekin, Bahar

N1 - Funding Information: Dr. Petra Ritter is supported by H2020 Research and Innovation Action grants VirtualBrainCloud 826421, Human Brain Project 785907, 945539, and ERC 683049; German Research Foundation CRC 1315, CRC 936, and RI 2073/6‐1; Berlin Institute of Health & Foundation Charité, Johanna Quandt Excellence Initiative. Funding Information: Dr. Harald Hampel is an employee of Eisai Inc., serves as Senior Associate Editor for the journal . Before May 2019, he had received lecture fees, travel funding, and research grants from several Pharmacological Companies. Alzheimer's & Dementia Funding Information: Dr. Brendan Lucey is supported by the National Institute on Aging (K76 AG054863). Funding Information: Dr. Claudio Babiloni is supported by European Committee (H2020‐EU.1.3.1.H2020‐MSCA‐ITN‐ETN‐2016 project with short title “BBDiag”). Funding Information: The present paper was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the electrophysiology professional interest area (PIA). EPIA is committed to (1) exploit EEG biomarkers for improving the understanding of neurophysiological mechanisms underlying Alzheimer's disease and age-related dementing disorders at micro, meso, and macro spatial scale and (2) promoting clinical applications. Of note, the views and opinions expressed by authors in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART, or the Alzheimer's Association. Furthermore, this manuscript was facilitated by the Global Brain Consortium (https://globalbrainconsortium.org). The Global Brain Consortium is committed to achieving the vision of improved and more equitable health outcomes worldwide by strengthening linkages between neuroscientists across borders and disciplines. Quantitative EEG techniques and biomarkers are considered an important resource for brain research and clinical applications in neurologic and psychiatric diseases, especially in lower- and middle-income countries. We thank Prof. Philip Scheltens, Dr. Cornelius Stam, Dr. Wilhelm de Haan, and Dr. Alida Gouw of Center at the VU University Medical Center in Amsterdam for the constructive and helpful revision of an original version of the manuscript. We also thank Dr. Claire Sexton of Alzheimer's Association for the same reasons. Publisher Copyright: © 2021 the Alzheimer's Association

PY - 2021/9

Y1 - 2021/9

N2 - The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

AB - The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

KW - Alzheimer's disease

KW - biomarkers

KW - clinical trials

KW - dementia

KW - electroencephalography (EEG)

KW - eyes-closed resting state condition

KW - The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)

UR - http://www.scopus.com/inward/record.url?scp=85104694674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104694674&partnerID=8YFLogxK

U2 - 10.1002/alz.12311

DO - 10.1002/alz.12311

M3 - Review article

C2 - 33860614

AN - SCOPUS:85104694674

SN - 1552-5260

VL - 17

SP - 1528

EP - 1553

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 9

ER -

Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this